Bio-Techne announced fiscal Q4 2025 revenues of $317 million, a 4% year-over-year increase, driven by strong performance in protein sciences and cell therapy workflow consumables despite a slight decline in spatial biology and diagnostic segments. The company proceeded with plans to divest its Exosome Diagnostics business to MDxHealth for $15 million. While navigating headwinds including constrained NIH research funding and geopolitical factors affecting instrument placements in certain markets, Bio-Techne maintained a positive growth outlook and highlighted investments in innovation and customer-centric solutions.